Rosmarinic Acid Blocks Chemo-Induced Heart Aging via 14-3-3/Foxo1 Pathway
A natural polyphenol found in herbs shields heart cells from doxorubicin-induced senescence, potentially making cancer chemotherapy safer.
Summary
Doxorubicin, a widely used chemotherapy drug, damages the heart partly by driving cardiomyocytes into premature senescence. Researchers at China Agricultural University found that rosmarinic acid (RA), a polyphenol found in rosemary and other herbs, can counter this effect. In both cell models and mice, RA reduced hallmarks of cellular senescence including SA-β-gal activity, p16/p21 expression, and inflammatory SASP factors like IL-6 and TNF-α. Mechanistically, RA upregulates the protein 14-3-3θ, which promotes Foxo1 phosphorylation and prevents it from entering the nucleus to activate senescence programs. In mice, RA improved survival, preserved cardiac function, and reduced fibrosis and mitochondrial damage caused by doxorubicin treatment.
Detailed Summary
Cardiotoxicity is one of the most serious side effects of doxorubicin (DOX), a frontline chemotherapy agent used in many cancers. Emerging evidence implicates cardiomyocyte senescence — a state of irreversible cell cycle arrest accompanied by inflammatory secretion — as a key driver of this damage. Finding ways to suppress this senescence without compromising cancer treatment is a major clinical priority.
Researchers screened a panel of natural polyphenolic compounds and identified rosmarinic acid (RA) as a potent inhibitor of DOX-induced senescence in HL-1 cardiomyocytes. RA treatment significantly reduced SA-β-galactosidase activity (a canonical senescence marker), lowered expression of cell cycle inhibitors p16 and p21, and suppressed secretion of pro-inflammatory senescence-associated secretory phenotype (SASP) factors including IL-6, IL-1β, and TNF-α.
Using advanced target-identification tools — Activity-Based Protein Profiling (ABPP), Cellular Thermal Shift Assay (CETSA), Microscale Thermophoresis, and molecular docking — the team pinpointed 14-3-3θ as a direct molecular target of RA. By upregulating 14-3-3θ, RA enhances phosphorylation of the transcription factor Foxo1, trapping it in the cytoplasm and preventing its nuclear translocation, which would otherwise activate senescence-related gene programs.
In a DOX-induced cardiotoxicity mouse model, RA administration improved survival rates, preserved echocardiographic cardiac function, reduced heart failure biomarkers, and attenuated histological damage including myocardial atrophy, fibrotic remodeling, and mitochondrial dysfunction.
While findings are compelling, the study is limited by its preclinical scope. Translation to humans requires clinical trials to confirm safety and efficacy alongside chemotherapy regimens.
Key Findings
- Rosmarinic acid reduced SA-β-gal activity, p16/p21 expression, and SASP factors in DOX-treated cardiomyocytes.
- RA directly targets 14-3-3θ, boosting Foxo1 phosphorylation and blocking its nuclear senescence-activating translocation.
- In mice, RA improved survival, cardiac function, and reduced fibrosis and mitochondrial damage from doxorubicin.
- ABPP and CETSA confirmed 14-3-3θ as a bona fide molecular target of rosmarinic acid.
- RA offers a dual benefit: anti-senescence cardioprotection without reported interference with chemotherapy efficacy.
Methodology
The study used DOX-induced senescent HL-1 cardiomyocytes in vitro with CCK8, SA-β-gal staining, RT-qPCR, and ELISA to assess senescence. Molecular targets were identified via ABPP, CETSA, MST, western blot, and molecular docking. In vivo validation used a DOX-treated mouse model assessed by echocardiography, histopathology, and immunofluorescence.
Study Limitations
This is a preclinical study conducted in cell lines and mice; human pharmacokinetics and dosing for RA remain unstudied in this context. The research does not directly assess whether RA affects doxorubicin's anti-tumor efficacy, a critical safety consideration. Long-term cardiac outcomes and potential off-target effects of 14-3-3θ upregulation require further investigation.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.